MRSN

Mersana Therapeutics, Inc. (MRSN) Economic Moat Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Overall Score

Scale Market Position

Small market cap and limited enterprise value indicate a niche market position.

Revenue base remains modest at 3.37 revenue per share, limiting scale advantages.

Profitability Returns

Margins are deeply negative on an operating and net basis, with EBIT margin at -3.22 and net margin at -3.33.

Returns are poor, with ROIC at -2.42 and ROA at -0.89, showing no durable economic profit.

Balance Sheet Resilience

Liquidity is acceptable with a current ratio of 1.39 and cash ratio of 1.30.

Debt appears manageable in absolute terms, but negative earnings and cash flow weaken resilience.

Cash Generation Reinvestment

Operating cash flow and free cash flow are both negative, with FCF per share at -11.05.

High R&D and SG&A intensity relative to revenue suggests heavy reinvestment without current payoff.

Moat Indicators

Gross margin is very high at 98.29%, but it is not translating into durable operating profitability.

No clear evidence of pricing power, switching costs, or network effects is visible in the current financials.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mersana Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →